郭志德博士毕业于中国原子能科学研究院（导师：杜进研究员、张现忠教授）；于厦门大学公共卫生学院从事博士后研究并入选2017年度“博士后创新人才支持计划”（合作导师：张现忠教授）；2020年入职厦门大学并入选“南强青年拔尖人才支持计划”。主要围绕“放射性分子探针与分子影像”开展相关研究。迄今以第一作者/通讯作者在Clin Cancer Res、Angew Chem Int Ed Engl、Redox Biology、J Nucl Med、Eur J Nucl Med Mol Imaging、 J Med Chem、Adv Mater等权威期刊发表原创性成果60余篇。担任中国核学会同位素分会、放药分会理事、中华核医学实验学组成员等学术职务。获华夏医学科技奖、中华医学科技奖、首届放射性药物青年人才会议优秀成果奖、厦门大学富有转化潜力十佳成果奖、博新计划优秀创新成果奖、连续3次获得全国放射性药物与标记化合物学术会议优秀青年论文奖。

入选计划及主持项目

先后入选国家博新计划、南强青年拔尖人才支持计划、省级人才项目等。

主持国家自然科学基金面上项目、青年项目、校长基金、企业合作课题等十余项。

团队致力于放射性诊疗创新药物的研发及临床转化，已建立起聚焦于重大疾病诊疗的独特原创放射性药物研发平台，并与国内多家医院合作开展新药转化研究。近年来主持多项放射性新药研发及科技成果转化项目并支持企业获得多项药品临床试验批件。多项发明人成果实现企业转化。

主要研究领域

（1）新型诊疗探针的开发研究：通过化学、生物学手段创新探针设计、优化探针性能，开发功能性、智能化分子影像探针。

（2）系统性研究基于放射性药物targeting-triggering-therapy(3t)效应的免疫诊疗新范式；

招生/招聘

诚挚欢迎化学、生物学、药学、医学、公共卫生、材料学等专业的优秀学子们报考，一起探索放射性药物及分子影像新天地！同时，本团队招收科研助理及放药专项研发人员，有意者可随时发送简历或电话联系（长期有效）。更多信息详见公众号“厦一站MIPer”。

近五年成果列表（^#共同一作，*通讯作者）

[43] Yesen Li^#, Yanjie Wang^#, YaoxuanWang, Jinxiong Huang*, Zhide Guo*. Development and Evaluation of ⁶⁸Ga-Labeled TMTP1-Based Cyclic Peptide Probes for Targeting Hepatocellular Carcinoma. Molecular pharmaceutics 2025, 10.1021/acs.molpharmaceut.4c01123.

[42] Huanhuan Liu, Jia Liu, Yingxi Chen, Hongzhang Yang, Jianyang Fang, Xinying Zeng, Jingru Zhang, Shilan Peng, Yuanyuan Liang, Rongqiang Zhuang*, Gang Liu*, Xianzhong Zhang*, Zhide Guo*. Development of STING probes and visualization of STING in multiple tumor types. European Journal of Nuclear Medicine and Molecular Imaging 2024, 52:401-415.

[41] Yuanyuan Liang#, Xueqi Wang#, Yingxi Chen#, Xinying Zeng, Jia Liu, Zuoquan Zhao, Hongzhang Yang, Qinglin Zhang, Jindian Li*, Zhide Guo*, Xianzhong Zhang*. Development and Evaluation of [⁶⁸Ga]Ga-labeled Riboflavin Derivative for RFVT3-Targeted PET Imaging of Melanoma in Mice. Molecular Pharmaceutics 2024, 21:4960-4969.

[40] Jia Liu, Yuanyuan Liang, Hongzhang Yang, Xueqi Wang, Xinying Zeng, Rongqiang Zhuang, Jin Du*, Xianzhong Zhang*, Zhide Guo*. Small-molecule radiotracers for visualization of V-domain immunoglobulin suppressor of T cell activation. Journal of Medicinal Chemistry 2024, 67:17690-17700.

[39] Jindian Li, Xingfang Hong, Yingxi Chen, Bin Yin, Hongzhang Yang, Changrong Shi, Xinying Zeng, Deliang Zhang*, Zhide Guo*, Xianzhong Zhang*. MicroPET Imaging of Riboflavin Transporter 3 Expression in Myocardial Infarction/Reperfusion Rat Models with Radiofluorinated Riboflavin. ACS Pharmacology & Translational Science 2024, 7:2350-2357.

[38] Shilan Peng^#, Yuanyuan Liang^#, Haotian Zhu, Yike Wang, Yun Li, Zuoquan Zhao, Yesen Li, Rongqiang Zhuang, Lumei Huang*, Xianzhong Zhang*, Zhide Guo*. A Nitroreductase Responsive Probe for Early Diagnosis of Pulmonary Fibrosis Disease. Redox Biology 2024, 75:103294.

[37] Xueyuan Zeng^#, Hongwu Liu^#, Guolong Huang^#, Yanjie Wang, Wuhao Zhou, Yike Wang, Xuedong Chen, Xingxing Cheng, Rongqiang Zhuang, Jindian Li, Jianyang Fang*, Lumei Huang*, Xianzhong Zhang*, Zhide Guo*. Development of Preladenant-Based Radiotracers for Imaging A2AR in Tumors. Journal of Medicinal Chemistry 2024, 67:13056-13066.

[36] Xuedong Chen, Dongsheng Xia, Xueyuan Zeng, Lingxin Meng, Yanjie Wang, Huifeng Li, Jingru Zhang, Zuoquan Zhao, Rongqiang Zhuang, Jianyang Fang*, Xianzhong Zhang*, Zhide Guo*. Rational Design and Pharmacomodulation of ¹⁸F-Labeled Biotin/FAPI-Conjugated Heterodimers. Journal of Medicinal Chemistry 2024, 67:8361-8371.

[35] Lingxin Meng#, Jianyang Fang#, Jingru Zhang, Huifeng Li, Dongsheng Xia, Rongqiang Zhuang, Haojun Chen, Jinxiong Huang, Yesen Li*, Xianzhong Zhang*, Zhide Guo*. Rational Design and Comparison of Novel ^99mTc-Labeled FAPI Dimers for Visualization of Multiple Tumor Types. Journal of Medicinal Chemistry. 2024;67:8460-8472.

[34] Jianyang Fang^#, Xiaobo Wang^#, Lingxin Meng, Jingru Zhang, Rongqiang Zhuang, Yesen Li, Xianzhong Zhang*, Zhide Guo*. Preclinical Evaluation of ¹³¹I/¹⁸F-Labeled Covalent Small-Molecule Inhibitors for STING Status Imaging. ACS Pharmacology & Translational Science 2024, 7:1783-1794.

[33] Jingchao Li^#, Yun Li^#, Jiang Ming^#, Xinying Zeng, Tingting Wang, Hongzhang Yang, Hongwu Liu, Yibo An, Xun Zhang, Rongqiang Zhuang, Xinhui Su*, Zhide Guo*, Xianzhong Zhang*. Progressive Optimization of Lanthanide Nanoparticle Scintillators for Enhanced Triple-Activated Radioluminescence Imaging. Angew Chem Int Ed Engl 2024, e202401683.

[32] Hongzhang Yang^#, Xinying Zeng^#, Jia Liu^#, Jingchao Li, Yun Li, Qinglin Zhang, Linlin Shu, Huanhuan Liu, Xueqi Wang, Yuanyuan Liang, Ji Hu, Lumei Huang*, Zhide Guo*, Xianzhong Zhang*. A Proof-of-Concept Study on Bioorthogonal-based Pretargeting and Signal Amplify Radiotheranostic Strategy. Journal of Nanobiotechnology 2024, 22:101.

[31] Jianyang Fang^#, Jingru Zhang, Lingxin Meng, Huifeng Li, Dongsheng Xia, Yaoxuan Wang, Hao Chen, Zhenhuan Liao, Rongqiang Zhuang, Yesen Li, Xianzhong Zhang*, Zhide Guo*. ¹⁸F-Labeled Amidobenzimidazole Analogue for Visualizing STING Expression in Tumor. Molecular pharmaceutics 2024, 21:1942-1951.

[30] Yanjie Wang, Yuan Sun, Xueyuan Zeng, Rongqiang Zhuang, Jinxiong Huang, Xianzhong Zhang*, Zhide Guo*, Yesen Li*. Ga–Labeled TMTP1 modified with D-amino acid for Positron Emission Tomography diagnosis of highly metastatic hepatocellular carcinoma. Journal of Medicinal Chemistry 2024, 67:2165-2175.

[29] Hongzhang Yang^#, Xinying Zeng^#, Jia Liu^#, Xuejun Wen, Huanhuan Liu, Yuanyuan Liang, Xueqi Wang, Jianyang Fang, Qinglin Zhang, Jindian Li*, Xianzhong Zhang*, Zhide Guo*. Development of Small-molecular-based Radiotracers for PET Imaging of PD-L1 Expression and Guiding the PD-L1 Therapeutics. European Journal of Nuclear Medicine and Molecular Imaging 2024, 51:1582-1592.

[28] Xuejun Wen^#, Xueyuan Zeng^#, Jia Liu^#, Xinying Zeng, Yiren Zhang, Xingxing Cheng, Jinxiong Huang, Yesen Li, Rongqiang Zhuang*, Xianzhong Zhang*, Zhide Guo*. In vivo Comparative Study of Radiolabeled Folate Receptor Targeting Albumin Probes for Atherosclerosis Plaque Imaging. Bioconjugate Chemistry 2023, 34:2387-2397.

[27] Huanhuan Liu#, Yuan Sun#, Jindian Li, Yingxi Chen, Jia Liu, Jianyang Fang, Hongzhang Yang, Lixia Feng, Shilan Peng, Rongqiang Zhuang, Zhide Guo*, Xianzhong Zhang*. Development of an 18F-labeled acridone analog for stimulator of interferon genes targeting and visualization in the tumor microenvironment via PET. Molecular Pharmaceutics 2023, 20: 3529-3538.

[26] Yizhen Pang^#, Liang Zhao^#, Jianyang Fang^#, Jianhao Chen, Lingxin Meng, Long Sun, Hua Wu, Zhide Guo*, Qin Lin, Haojun Chen*. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy. Journal of Nuclear Medicine 2023, 64:1449-1455.

[25] Xuejun Wen^#, Pengfei Xu^#, Xinying Zeng^#, Jia Liu, Chao Du, Xueyuan Zeng, Xingxing Cheng, Xueqi Wang, Yuanyuan Liang, Tianzhi Zhao, Hongzhang Yang, Huifeng Li, Lingxin Meng, Jianyang Fang, Hongwu Liu, Zijian Zhou, Jingjing Zhang*, Xianzhong Zhang*, Zhide Guo*, Xiaoyuan Chen*. Development of [¹⁷⁷Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. European Journal of Nuclear Medicine and Molecular Imaging 2023, 50: 2846-2860.

[24] Zichen Ye^#, Yun Li^#, Jingchao Li, Xinyan Hu, Jinyang Zheng, Gongxin Zhang, Sijin Xiang, Tianbao Zhu, Zhide Guo*, Xiaolan Chen*. Pd@Ir-LOD Multienzyme Utilizing Endogenous Lactate Consumption Cooperates with Photothermal for Tumor Therapy. Nano Research 2023. Doi: 10.1007/s12274-023-5764-1.

[23] Xuejun Wen, Changrong Shi, Xinying Zeng, Liang Zhao, Lanlin Yao, Zhida Liu, Lixia Feng, Deliang Zhang, Jinxiong Huang, Yesen Li, Qin Lin, Haojun Chen, Rongqiang Zhuang, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. A paradigm of cancer immunotherapy based on 2-[¹⁸F]FDG and anti-PD-L1 mAb combination to enhance the anti-tumor effect. Clinical Cancer Research 2022, 28:2923-2937.

[22] Lingxin Meng^#, Jianyang Fang^#, Liang Zhao^#, Tingting Wang, Pu Yuan, Zuoquan Zhao, Rongqiang Zhuang, Qin Lin, Haojun Chen*, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. Rational design and pharmacomodulation of protein-binding theranostic radioligands for targeting fibroblast activation protein. Journal of Medicinal Chemistry 2022, 65:8245-8257.

[21] Xuejun Wen^#, Xinying Zeng^#, Jia Liu, Yiren Zhang, Changrong Shi, Xiaoming Wu, Rongqiang Zhuang, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. Synergism of ⁶⁴Cu-labeled RGD with anti-PD-L1 immunotherapy for the long-acting antitumor effect. Bioconjugate Chemistry 2022, 33:2170-2179.

[20] Tingting Wang^#, Pengfei Xu^#,*, Jianyang Fang, Cijuan Li, Xinying Zeng, Jia Liu, Lingxin Meng, Rongqiang Zhuang, Xianzhong Zhang*, Xinhui Su*, Zhide Guo*. Synthesis and preclinical evaluation of a ⁶⁸Ga-labeled pyridiny benzamide dimer for malignant melanoma imaging. Molecular Pharmaceutics 2022, 20:1015-1024.

[19] Xuejun Wen^#, Xinying Zeng^#, Changrong Shi, Jia Liu, Yiren Zhang, Mengqi Shi, Jingchao Li, Haojun Chen, Rongqiang Zhuang, Xiaoyuan Chen*, Xianzhong Zhang*, Zhide Guo*. Optimum combination of radiopharmaceuticals-based targeting-triggering-therapy effect and PD-L1 blockade immunotherapy. Advanced Therapeutics. Doi: 10.1002/adtp.202200193.

[18] Liang Zhao^#, Bo Niu^#, Jianyang Fang^#, Yizhen Pang, Siyang Li, Chengrong Xie, Long Sun, Xianzhong Zhang, Zhide Guo*, Qin Lin, Haojun Chen*. Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of ⁶⁸Ga-labeled FAPI dimer. Journal of Nuclear Medicine 2022, 63:862-868.

[17] Xuejun Wen^#, Pengfei Xu^#, MengqiShi#, Jia Liu, Xinying Zeng, Yiren Zhang, Changrong Shi, Jingchao Li, Zhide Guo*, Xianzhong Zhang*, Pek-Lan Khong*, Xiaoyuan Chen*. Evans blue-modified radiolabeledfibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics 2022, 12: 422-433.

[16] Jie Zang^#, Xuejun Wen^#, Rong Lin^#, Xinying Zeng, Chao Wang, Mengqi Shi, Xueyuan Zeng, Jiaying Zhang, Xiaoming Wu, Xianzhong Zhang, Weibing Miao*, Pengfei Xu*, Zhide Guo*, Jingjing Zhang*, Xiaoyuan Chen*. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [⁶⁸Ga]Ga-FAPI-RGD. Theranostics 2022, 12: 7180-7190.

[15] Xuejun Wen, Changrong Shi, Liu Yang, Xinying Zeng, Xiaoru Lin, Jinxiong Huang, Yesen Li, Rongqiang Zhuang, Haibo Zhu, Zhide Guo*, Xianzhong Zhang*. A radioiodinated FR-β-targeted tracer with improved pharmacokinetics through modification with an albumin binder for imaging of macrophages in AS and NAFL. European Journal of Nuclear Medicine and Molecular Imaging 2022, 49:503-516.

[14] Yiren Zhang, Xuejun Wen, Yanjie Wang, Xia Yang, Yingxi Chen, Xinying Zeng, Yesen Li, Jinxiong Huang, Zhide Guo*, Xianzhong Zhang*. Longitudinal MicroSPECT Imaging of Systemic Sclerosis Model Mice with ^99mTc-HYNFA via FR Targeting. Molecular Pharmaceutics 2023, 20:473-480.

[13] Jianyang Fang^#, Lixia Feng^#, Lingxin Meng^#, Xiaobo Wang, Huanhuan Liu, Lumei Huang, Deliang Zhang, Jindian Li, Rongqiang Zhuang, Zhide Guo*, Xianzhong Zhang*. A novel ¹⁸F-labeled agonist for PET imaging of stimulator of interferon gene expression in tumor-bearing mice. European Journal of Nuclear Medicine and Molecular Imaging 2022, 50:27-37.

[12] Lumei Huang^#, Jianyang Fang^#, Shouqiang Hong, Huanhuan Liu, Haotian Zhu, Lixia Feng, Rongqiang Zhuang, Xilin Zhao, Zhide Guo*, Xianzhong Zhang*. MicroPET imaging of bacterial infection with nitroreductase-specific responsive ¹⁸F-labelled nitrogen mustard analogues. European Journal of Nuclear Medicine and Molecular Imaging 2022, 49:2645-2654.

[11] Huanhuan Liu^#, Xiaoru Lin^#, Duo Xu, Jingchao Li, Jianyang Fang, Jindian Li, Lingxin Meng, Xinying Zeng, Yesen Li, Jinxiong Huang, Zhide Guo*, and Xianzhong Zhang*. Radioiodinated ethinylestradiol derivatives for estrogen receptor targeting breast cancer imaging. ACS Medicinal Chemistry Letters 2022, 13:203-210.

[10] Jindian Li^#, Yingxi Chen^#, Chenyu Peng^#, Xingfang Hong^#, Huanhuan Liu, Jianyang Fang, Rongqiang Zhuang, Weimin Pan, Deliang Zhang*, Zhide Guo*, Xianzhong Zhang*. Micro-SPECT Imaging of Acute Ischemic Stroke with Radioiodinated Riboflavin in Rat MCAO Models via Riboflavin Transporter Targeting. ACS Chemical Neuroscience 2022, 13:1966-1973.

[9] Lanlin Yao^#, Xuejun Wen^#, Wei Guo, Jianyang Fang, Xianzhong Zhang, Zhide Guo*, Jinxiong Huang*, Yesen Li¹*. A novel radiolabeled TMTP1 for long-acting hepatocellular carcinoma therapeutics. Molecular Pharmaceutics 2022, 19: 3178-3186.

[8] Lixia Feng, Jianyang Fang, Xinying Zeng, Huanhuan Liu, Jingru Zhang, Zhide Guo*, Rongqiang Zhang*, Xianzhong Zhang*. ⁶⁸Ga-labeled maleimide for blood pool and lymph PET imaging through covalent bonding to serum albumin in vivo. ACS Omega 2022, 7:28597-28604.

[7] Xuejun Wen, Xueyuan Zeng, Xingxing Cheng, Xinying Zeng, Jia Liu, Yiren Zhang, Yesen Li, Haojun Chen, Jinxiong Huang*, Zhide Guo*, Xiaoyuan Chen*, Xianzhong Zhang*. PD-L1-targeted radionuclide therapy combined with αPD-L1 antibody immunotherapy synergistically improves the antitumor effect. Molecular Pharmaceutics 2022, 19:3612-3622.

[6] Duo Xu^#, Xiaoru Lin^#, Xinying Zeng^#, Xuejun Wen, Jingchao Li, Yesen Li, Jinxiong Huang, Xiaoyuan Chen, Zhide Guo*, Xianzhong Zhang*. Radioiodinated 4-(p-iodophenyl) butanoic acid modified estradiol derivative for ER targeting SPECT imaging. Analytical Chemistry 2021, 93:13998-14006.

[5] Jingchao Li^#, Shuqi Dai^#, Ruixue Qin, Changrong Shi, Jiang Ming, Xinying Zeng, Xuejun Wen, Rongqiang Zhuang, Xiaoyuan Chen*, Zhide Guo*, Xianzhong Zhang*. Ligand Engineering of Titanium-Oxo Nanoclusters for Cerenkov Radiation-Reinforced Photo/Chemodynamic Tumor Therapy. ACS Appl Mater Interfaces 2021, 13: 54727-54738.

[4] Zhide Guo^#, Liu Yang^#, Mei Chen^#, Xuejun Wen, Huanhuan Liu, Jingchao Li, Duo Xu, Yuanyuan An, Changrong Shi, Jindian Li, Xinhui Su, Zijing Li, Ting Liu, Rongqiang Zhuang, Nanfeng Zheng*, Haibo Zhu*, Xianzhong Zhang*. Molecular imaging of advanced atherosclerotic plaques with folate receptor-targeted 2D nanoprobes. Nano Research 2020, 13:173-182.

[3] Xuejun Wen, Changrong Shi, Liang Zhao, Lanlin Yao, Duo Xu, Xiaoru Lin, Xinhui Su, Ting Liu, Rongqiang Zhuang, Qin Lin*, Haojun Chen*, Zhide Guo*, Xianzhong Zhang*. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma. Nuclear Medicine and Biology 2020, 86-87:44-51.

[2] Xuejun Wen, Changrong Shi, Duo Xu, Pu Zhang, Zizhen Li, Jindian Li, Xinhui Su, Rongqiang Zhuang, Ting Liu, Zhide Guo*, Xianzhong Zhang*. Radioiodinated portable albumin binder as a versatile agent for in vivo imaging with single-photon emission computed tomography. Molecular Pharmaceutics 2019, 16: 816-824.

[1] Haojun Chen, Liang Zhao, Kaili Fu, Qiuming Lin, Xuejun Wen, Orit Jacobson, Long Sun, Hua Wu, Xianzhong Zhang*, Zhide Guo*, Qin Lin*, Xiaoyuan Chen*. Integrin α_vβ₃-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy. Theranostics 2019, 9:7948-7960.